new "designer estrogen," Evista
January 1999
Lilly is now promoting their new "designer estrogen," Evista.
It'll be used as an alternative to estrogen...to prevent osteoporosis in postmenopausal women.
Evista (raloxifene) is a selective estrogen receptor modulator...in the same class as tamoxifen. It mimics the effects of estrogen in some tissues...but not in others.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote